Therapeutics MD GAAP EPS of $0.04
TherapeuticsMD (TXMD) reported Q3 2026 GAAP EPS of $0.04, with license revenue up 60.6% YoY to $1.3M. Cash reserves stood at $10.4M as of Q3 2026. The stock rose 2.75%.
How this was made
The 30-second read
Why it matters
The Q3 earnings release provides the first public numbers for the quarter, offering a modest data point for valuation.
Market read
A small earnings release with modest beat; limited trading relevance beyond the stock itself.
What to watch
Potential future licensing deals and cash runway are not detailed in the release.
Background
TherapeuticsMD is a micro‑cap biotech focused on licensing its drug candidates.
Ticker impact
TherapeuticsMD reported Q3 GAAP EPS of $0.04 and $1.3M license revenue, a fresh earnings disclosure for the micro‑cap.
likely slight upward pressure as the market prices the earnings beat and revenue growth.
The company posted a modest EPS beat and 60% revenue increase, but the absolute numbers are tiny for a micro‑cap, limiting material impact.
Market effects
Limited; reflects modest growth in the biotech licensing segment.
None
Low
Counterpoint
The earnings beat may be overstated given the tiny scale; investors could remain cautious.
Key entities
- CompanyTherapeuticsMD, Inc.
Biotech firm reporting Q3 results.
